Danazol (Capsule)

dailymed-instance:drugs, http://www4.wiwiss.fu-berlin.de/drugbank/vocab/resource/class/Offer

dailymed-ingredient:danazol

Use of danazol in pregnancy is contraindicated. A sensitive test (e.g., beta subunit test if available) capable of determining early pregnancy is recommended immediately prior to start of therapy. Additionally a nonhormonal method of contraception should be used during therapy. If a patient becomes pregnant while taking danazol, administration of the drug should be discontinued and the patient should be apprised of the potential risk to the fetus. Exposure to danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received. (See PRECAUTIONS: Pregnancy, Teratogenic Effects.) Thromboembolism, thrombotic and thrombophlebitic events including sagittal sinus thrombosis and life-threatening or fatal strokes have been reported. Experience with long-term therapy with danazol is limited. Peliosis hepatis and benign hepatic adenoma have been observed with long-term use. Peliosis hepatis and hepatic adenoma may be silent until complicated by acute, potentially life-threatening intra-abdominal hemorrhage. The physician therefore should be alert to this possibility. Attempts should be made to determine the lowest dose that will provide adequate protection. If the drug wasbegun at a time of exacerbation of hereditary angioneurotic edema due to trauma, stress or other cause, periodic attempts to decrease or withdraw therapy should be considered. Danazol has been associated with several cases of benign intracranial hypertension also known as pseudotumor cerebri. Early signs and symptoms of benign intracranial hypertension include papilledema, headache, nausea and vomiting, and visual disturbances. Patients with these symptoms should be screened for papilledema and, if present, the patients should be advised to discontinue danazol immediately and be referred to a neurologist for further diagnosis and care.

dailymed-ingredient:D&C_yellow_no._10, dailymed-ingredient:D&C_yellow_no._10_aluminum_lake, dailymed-ingredient:FD&C_blue_no._1_aluminum_lake, dailymed-ingredient:FD&C_blue_no._2_aluminum_lake, dailymed-ingredient:FD&C_red_no._40_aluminum_lake, dailymed-ingredient:FD&C_yellow_no._6, dailymed-ingredient:black_iron_oxide, dailymed-ingredient:gelatin, dailymed-ingredient:lactose_monohydrate, dailymed-ingredient:magnesium_stearate, dailymed-ingredient:pharmaceutical_glaze, dailymed-ingredient:propylene_glycol, dailymed-ingredient:silicon_dioxide, dailymed-ingredient:sodium_lauryl_sulfate, dailymed-ingredient:sodium_starch_glycolate, dailymed-ingredient:stearic_acid, dailymed-ingredient:titanium_dioxide

Danazol

http://www4.wiwiss.fu-berlin.de/dailymed/resource/organization/BARR_LABORATORIES,_INC.

Danazol